📋 Clinical Overview

Doxorubicin (Liposomal) is a pegylated, liposomal formulation of the anthracycline antibiotic doxorubicin. It is designed to encapsulate doxorubicin within liposomes, which are microscopic vesicles composed of a phospholipid bilayer. This encapsulation significantly alters the pharmacokinetics and biodistribution compared to conventional doxorubicin. The pegylated (stealth) coating helps evade detection by the mononuclear phagocyte system, leading to prolonged circulation time and preferential accumulation in tumor tissues with leaky vasculature, a phenomenon known as the Enhanced Permeability and Retention (EPR) effect. This results in higher intratumoral concentrations and reduced exposure to healthy tissues, particularly the heart, thereby mitigating the risk of cardiotoxicity. It is a cytotoxic, non-cell-cycle specific antineoplastic agent.

💊 Dosage & Administration

Adult: Dose is based on Body Surface Area (BSA). **Kaposi's Sarcoma:** 20 mg/m² IV over 30 minutes, every 2-3 weeks. **Ovarian Cancer:** 50 mg/m² IV over 60 minutes, every 4 weeks. **Multiple Myeloma:** 30 mg/m² IV over 60 minutes on day 4 following bortezomib (which is given on days 1, 4, 8, & 11 of a 21-day cycle). Dose adjustments are based on hematological and non-hematological toxicity.
Pediatric: Safety and efficacy not established in children. Use only under strict supervision of pediatric oncologists in clinical trial settings or for life-threatening conditions.
Renal Adjusment: No specific dosage adjustment recommended for mild to moderate renal impairment. Use with caution in severe renal impairment (CrCl < 30 mL/min) due to lack of data. Monitor for increased toxicity.
Hepatic Adjusment: **Mild Impairment (Bilirubin 1.2–3.0 mg/dL):** Reduce dose by 25-50%. **Moderate to Severe Impairment (Bilirubin > 3.0 mg/dL):** Avoid use or consider a 50-75% dose reduction with extreme caution. Doxorubicin is extensively metabolized and excreted by the liver.
Instruction: **FOR IV INFUSION ONLY. NOT FOR INTRAMUSCULAR, SUBCUTANEOUS, OR INTRATHECAL USE. FATAL IF GIVEN INTRATHECALLY.** 1. Handle with cytotoxic precautions (gloves, gown, eye protection). 2. Dilute prescribed dose in 250 mL of 5% Dextrose Injection (D5W). **DO NOT USE SALINE or any other diluent.** 3. Do not mix with other drugs or heparin. Use a separate line. 4. Administer using a controlled infusion device over 30-60 minutes as per indication. 5. Use an IV line with a free-flowing IV solution (D5W) to prevent extravasation. Avoid veins over joints or in limbs with compromised circulation. 6. Observe for infusion reactions (flushing, shortness of breath, back pain). Pre-medication with antihistamines and corticosteroids is common.

⚠️ Contraindications

History of severe hypersensitivity reaction to doxorubicin, other anthracyclines, or any component of the liposomal formulation (including polyethylene glycol - PEG)
Severe myocardial insufficiency (NYHA Class III or IV)
Recent myocardial infarction (within last 6 months)
Severe hepatic impairment (Serum Bilirubin > 5 mg/dL)
Baseline neutrophil count < 1500 cells/mm³
Pregnancy and breastfeeding

🔬 Mechanism of Action

The liposomal formulation delivers doxorubicin to tumor sites. Once internalized by tumor cells, doxorubicin exerts multiple cytotoxic effects: 1) **Intercalation into DNA:** It inserts itself between base pairs of the DNA double helix, disrupting DNA and RNA synthesis. 2) **Topoisomerase II Inhibition:** It stabilizes the topoisomerase II-DNA complex, preventing religation of DNA strands and causing double-strand breaks. 3) **Generation of Reactive Oxygen Species (ROS):** Through redox cycling, it generates semiquinone free radicals and superoxide anions, leading to oxidative damage of cellular membranes, proteins, and DNA. 4) **Disruption of Cellular Membranes:** It binds to cell membrane lipids, altering fluidity and function.

🤕 Side Effects

Myelosuppression: Anemia, Leukopenia (Neutropenia), Thrombocytopenia
Nausea and Vomiting (less severe than conventional doxorubicin)
Stomatitis/Mucositis
Alopecia (reversible, less frequent than conventional)
Fatigue/Asthenia
Palmar-Plantar Erythrodysesthesia (PPE) or Hand-Foot Syndrome - a characteristic toxicity of this formulation
Constipation or Diarrhea
Anorexia
Skin rash/itching

🤰 Special Populations

Pregnancy: **Category D:** Positive evidence of human fetal risk. Doxorubicin is teratogenic and embryotoxic. Can cause fetal harm. Contraindicated in pregnancy. Women of childbearing potential must use effective contraception during and for at least 6 months after therapy. Men should use contraception during and for 3-6 months after therapy.

Lactation: Contraindicated. Doxorubicin is excreted in human milk. Potential for serious adverse reactions in the nursing infant. Discontinue breastfeeding during therapy.

Alcohol: Alcohol should be avoided as it may exacerbate mucositis, hepatotoxicity, and general dehydration.

Driving: May cause fatigue, dizziness, or malaise. Patients should be cautioned about operating machinery or driving if affected.

🔄 Drug Interactions

Other Cardiotoxic Agents (e.g., Trastuzumab, Cyclophosphamide, Daunorubicin): Markedly increased risk of cardiomyopathy and congestive heart failure. Avoid concurrent use or monitor LVEF very closely. Major
Cyclosporine, Verapamil: May increase intracellular doxorubicin concentrations, enhancing both efficacy and toxicity (especially hematological). Moderate
Phenobarbital, Phenytoin: May increase hepatic metabolism of doxorubicin, reducing its plasma concentration and efficacy. Moderate
Live Vaccines (e.g., MMR, Varicella, Yellow Fever): Risk of disseminated infection due to immunosuppression. Contraindicated during treatment. Major
Drugs metabolized by CYP2D6, CYP3A4: Doxorubicin may inhibit these enzymes, increasing levels of substrates (e.g., some beta-blockers, antidepressants). Moderate

🔁 Alternatives to Caelyx (Pegylated Liposomal - International Brand, may be available)

Same composition (Doxorubicin (Liposomal) (2mg/ml)), different brands:

Myocet (Non-pegylated Liposomal) Doxolip